The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/Ib study of the PARP inhibitor olaparib (O) with carboplatin (C) in BRCA1/2 mutation carriers with breast or ovarian cancer (Br/OvCa) (NCT00647062).
Jung-min Lee
No relevant relationships to disclose
Christina M. Annunziata
No relevant relationships to disclose
John L. Hays
No relevant relationships to disclose
Anne M. Noonan
No relevant relationships to disclose
Lori M. Minasian
No relevant relationships to disclose
JoAnne Zujewski
No relevant relationships to disclose
Minshu Yu
No relevant relationships to disclose
Jiuping Jay Ji
No relevant relationships to disclose
Tristan Sissung
No relevant relationships to disclose
Nicole D. Houston
No relevant relationships to disclose
Elise C. Kohn
No relevant relationships to disclose